• News
NI-3201, a PD-L1xCD28 bispecific antibody

NI-3201, a PD-L1xCD28 bispecific antibody

AACR Annual Meeting 2024 - Sara Majocchi -


Light Chain Bioscience is very pleased to have Sara Majocchi attend and present at the AACR annual meeting in San Diego, April 5-10, 2024

Sara Majocchi, PhD, Discovery Program Leader, will be presenting poster #5293 describing our NI-3201 program.

"Preclinical development of NI-3201, a PD-L1xCD28 bispecific antibody mediating CD28 costimulation upon PD-L1 blockade" will be exposed and presented on Tuesday April 9, 2024, 1:30 PM - 5:00 PM

reclinicalevelopment of NI-3201, a PD-L1xCD28 bispecific antibody mediating CD28 costimulation upon PD-L

Read poster #5293 [PDF]: 


San Diego Convention CenterSan Diego, California, United States

Back to News

New publication in Frontiers

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody


Read more

LinkedIn